Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Fachpsychotherapie Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Archives of Gynecology and Obstetrics
Erschienen in:

07.04.2020 | Gynecologic Endocrinology and Reproductive Medicine

Protective effect of oxytocin on a methotrexate-induced ovarian toxicity model

verfasst von: Ismet Hortu, Gokay Ozceltik, Ahmet Mete Ergenoglu, Gurkan Yigitturk, Ozum Atasoy, Oytun Erbas

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Although cancer predominantly affects people at older ages, a substantial number of patients, like breast cancer patients, are diagnosed before they have completed their families or even before giving birth. Furthermore, cytotoxic chemotherapy may be required in addition to treat cancer survivors. The present study was conducted to investigate the protective effect of oxytocin (OT) on methotrexate (MTX)-induced ovarian toxicity in rats.

Methods

Eighteen adult female Sprague–Dawley rats were used in the study. All rats were divided randomly into three groups. The control group (n = 6) received no treatment. The remaining 12 rats received a single dose of 20 mg/kg of MTX. Half of the rats (n = 6) were treated with 1 mg/kg/day of saline, and the other half (n = 6) were treated with 160 µg/kg/day of OT for 21 days. Then, blood samples were collected for biochemical analysis, and an ovariectomy was performed for histopathological examination.

Results

Plasma malondialdehyde (MDA) and transforming growth factor-β (TGF-β) levels were significantly lower in the MTX + OT group compared to the MTX + saline group (p = 0.000036 for MDA; p = 0.0044 for TGF-β). AMH levels were also significantly higher in the MTX + OT group than in the MTX + saline group (p = 0.000036). The ovarian fibrosis percent was also notably lower in the MTX + OT group than in the MTX + saline group (p = 0.000036).

Conclusion

On the basis of these findings, OT is a promising agent for ameliorating harmful effects of MTX on rat ovaries in an experimental model.
Literatur
1.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424CrossRef
2.
Elgindy EA, El-Haieg DO, Khorshid OM, El I, Abdeldawad M, Sallam HN, Abou-Setta AM (2013) Gonadotrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. Obstet Gynecol 121:78–86CrossRef
3.
Roness H, Kalich-Philosoph L, Meirow D (2014) Prevention of chemotherapy-induced ovarian damage: possible roles for hormonal and non-hormonal attenuating agents. Hum Reprod Update 20:759–774CrossRef
4.
Kasum M, Beketic-Oreskovic L, Peddi PF, Oreskovic S, Johnson RH (2014) Fertility after breast cancer treatment. Eur J Obstet Gynecol Reprod Biol 173:13–18CrossRef
5.
Balachandren N, Davies M (2017) Fertility, ovarian reserve and cancer. Maturitas 105:64–68CrossRef
6.
Ganz PA, Land SR, Geyer CE Jr et al (2011) Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol 29:1110–1116CrossRef
7.
Cosgrove CM, Salani R (2019) Ovarian effects of radiation and cytotoxic chemotherapy damage. Best Pract Res Clin Obstet Gynaecol 55:37–48CrossRef
8.
Khan ZA, Tripathi R, Mishra B (2012) Methotrexate: a detailed review on drug delivery and clinical aspects. Expert Opin Drug Deliv 9:151–169CrossRef
9.
Iwase A, Nakamura T, Nakahara T, Goto M, Kikkawa F (2015) Anti-Müllerian hormone and assessment of ovarian toxic treatment: a systematic narrative review. Reprod Sci 22:519–526CrossRef
10.
Pergialiotis V, Frountzas M, Prodromidou A, Prapa S, Perrea DN, Vlachos GD (2016) Propranolol and oxytocin versus oxytocin alone for induction and augmentation of labor: a meta-analysis of randomized trials. Arch Gynecol Obstet 293:721–729CrossRef
11.
Ragy MM, Aziz NM (2017) Prevention od renal ischemia/reperfusion-induced renal and hepatic injury in adult male Albino rats by oxytocin: role of nitric oxide. J Basic Clin Physiol Pharmacol 28:615–621CrossRef
12.
Alizadeh AM, Faghihi M, Khori V, Sohanaki H, Pourkhalili K, Mohammadghasemi F, Mohsenikia M (2012) Oxytocin protects cardiomyocytes from apoptosis induced by ischemia-reperfusion in rat heart: role of mitochondrial ATP-dependent potassium channel and permeability transition pore. Peptides 36:71–77CrossRef
13.
Gökçe A, Oktar S, Koc A, Yonden Z (2011) Protective effects of thymoquinone against methotrexate-induced testicular injury. Hum Exp Toxicol 30:897–903CrossRef
14.
Erbaş O, Akman L, Yavaşoğlu A, Terek MC, Akman T, Taskiran D (2014) Oxytocin improves follicular reserve in a cisplatin-induced gonadotoxicity model in rats. Biomed Res Int 2014:703691CrossRef
15.
Zeb A, Ullah F (2016) A simple spectrophotometric method for the determination of thiobarbituric acid reactive substances in fried fast foods. J Anal Methods Chem 2016:9412767CrossRef
16.
Bedoschi G, Navarro PA, Oktay K (2016) Chemotherapy-induced damage to ovary: mechanisms and clinical impact. Future Oncol 12:2333–2344CrossRef
17.
Vitale SG, Rossetti D, Tropea A, Biondi A, Laganà AS (2017) Fertility sparing surgery for stage IA type I and G2 endometrial cancer in reproductive-aged patients: evidence-based approach and future perspectives. Updates Surg 69:29–34CrossRef
18.
Committee on Practice Bulletin-Gynecology (2018) ACOG practice bulletin No. 191: tubal ectopic pregnancy. Obstet Gynecol 131:e65–e77CrossRef
19.
Hortu İ, Akman L, Akdemir A, Ergenoğlu M, Yeniel Ö, Şendağ F (2017) Management of ectopic pregnancy in unusual location: five-year experience in a single center. J Clin Exp Invest 8:90–95
20.
Padmanabhan S, Triphathi DN, Vikram A, Ramarao P, Jena GB (2009) Methotrexate-induced cytotoxicity and genotoxicity in germ cells of mice: intervention of folic and folinic acid. Mutat Res 673:43–52CrossRef
21.
Armagan A, Uzar E, Uz E, Yilmaz HR, Kutluhan S, Koyuncuoglu HR, Soyupek S, Cam H, Serel TA (2008) Caffeic acid phenethyl ester modulates methotrexate-induced oxidative stress in testes of rat. Hum Exp Toxicol 27:547–552CrossRef
22.
Delyon J, Ortonne N, Benayoun E, Moroch J, Wolkenstein P, Sbidian E, Chosidow O (2015) Low-dose methotrexate-induced skin toxicity: keratinocyte dystrophy as a histologic marker. J Am Acad Dermatol 73:484–490CrossRef
23.
Mohamed DI, Khairy E, Tawfeek SS, Habib EK, Fetouh MA (2019) Coenzyme Q10 attenuates lung and liver fibrosis via modulation of autophagy in methotrexate treated rat. Biomed Pharmacother 109:892–901CrossRef
24.
Norona LM, Nguyen DG, Gerber DA, Presnell SC, Mosedale M, Watkins PB (2019) Bioprinted liver provides early insight into the role of Kupffer cells in TGF- β1 and methotrexate-induced fibrogenesis. PLoS ONE 14:e0208958CrossRef
25.
Taylor HS, Pal L, Seli E (2020) Speroff’s clinical gynecologic endocrinology and infertility. In: Taylor HS, Pal L, Seli E (eds), Amenorrhea, 9th edn. Wolters Kluwer, New York, pp 821–939
26.
Soylu Karapinar O, Pinar N, Özcan O, Özgür T, Dolapçıoğlu K (2017) Protective effect of alpha-lipoic acid in methotrexate-induced ovarian oxidative injury and decreased ovarian reserve in rats. Gynecol Endocrinol 33:653–659CrossRef
27.
Wang P, Wang SC, Yang H, Lv C, Jia S, Liu X, Wang X, Meng D, Qin D, Hui Z, Wang YF (2019) Therapeutic potential of oxytocin in atherosclerotic cardiovascular disease: mechanisms and signalling pathways. Front Neurosci 13:454CrossRef
28.
Al-Amran F, Shahkolahi M (2013) Oxytocin ameliorates the immediate myocardial injury in rat heart transplant through downregulation of neutrophil-dependent myocardial apoptosis. Transplant Proc 45:2506–2512CrossRef
29.
Clodi M, Vila G, Geyeregger R, Riedl M, Stulnig TM, Struck J, Luger TA, Luger A (2008) Oxytocin alleviates the neuroendocrine and cytokine response to bacterial endotoxin in healthy men. Am J Physiol Endocrinol Metab 295:E686–E691CrossRef
30.
La Rosa VL, Shah M, Kahramanoglu I et al (2019) Quality of life and fertility preservation counseling for women with gynecological cancer: an integrated psychological and clinical perspective. J Psychosom Obstet Gynaecol 2:1–7
31.
Turner NH, Partridge A, Sanna G, Di Leo A, Biganzoli L (2013) Utility of gonadotropin—releasing hormone agonists for fertility preservation in young breast cancer patients: the benefit remains uncertain. Ann Oncol 24:2224–2235CrossRef
32.
Gerber B, Ortmann O (2014) Prevention of Early Menopause Study (POEMS): is it possible to preserve ovarian function by gonadotropin releasing hormone analogs (GnRHa)? Arch Gynecol Obstet 290:1051–1053CrossRef
33.
Del Mastro L, Boni L, Michelotti A et al (2011) Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 306:269–276PubMed
34.
Ethics Committee of the American Society for Reproductive Medicine (2018) Fertility preservation and reproduction in patients facing gonadotoxic therapies: an Ethics Committee opinion. Fertil Steril 110:380–386CrossRef
Metadaten
Titel
Protective effect of oxytocin on a methotrexate-induced ovarian toxicity model
verfasst von
Ismet Hortu
Gokay Ozceltik
Ahmet Mete Ergenoglu
Gurkan Yigitturk
Ozum Atasoy
Oytun Erbas
Publikationsdatum
07.04.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 5/2020
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-020-05534-1

Weitere Artikel der Ausgabe 5/2020

Mild stimulation protocol vs conventional controlled ovarian stimulation protocol in poor ovarian response patients: a prospective randomized controlled trial

  • Gynecologic Endocrinology and Reproductive Medicine

The effect of meconium-stained amniotic fluid on perinatal outcome in pregnancies complicated by preterm premature rupture of membranes

  • Maternal-Fetal Medicine

Relationship between preterm birth and post-partum periodontal maternal status: a hospital-based Romanian study

  • Maternal-Fetal Medicine

Impact of embryo quality and endometrial thickness on implantation in natural cycle IVF

  • Open Access
  • Gynecologic Endocrinology and Reproductive Medicine

Significance of lymph node ratio on survival of women with borderline ovarian tumors

  • Gynecologic Oncology

Risk factors and maternal outcomes following preterm premature rupture of membrane in the second trimester of gestation

  • General Gynecology

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Osteoporose-Indizes offenbar wenig sinnvoll bei jüngeren Frauen

In einer US-Studie war keiner von drei getesteten Osteoporose-Indizes verlässlich genug, um bei postmenopausalen Frauen unter 65 Jahren ein klinisch relevantes Frakturrisiko zu erkennen.

Einleitung bei Zwillingsgeburt mit Sectiorisiko assoziiert

Einleitung ja oder nein? Besonders bei Schwangerschaften mit Zwillingen ist diese Entscheidung relevant. Wird die Geburt eingeleitet, steigt das Risiko für eine Sectio deutlich. Das hat nun eine Studie aus der Schweiz ergeben.

Junge Brustkrebspatientinnen zum Durchhalten motivieren

Patientinnen, die in jungen Jahren an Hormonrezeptor-positivem Brustkrebs erkranken, neigen dazu, die adjuvante endokrine Therapie auszusetzen oder abzubrechen. Die schlechte Therapiepersistenz scheint die Rückkehr des Tumors zu begünstigen.

Krebsscreeningprogramme erreichen Menschen mit kognitiver Beeinträchtigung schlechter

Daten aus den Niederlanden zeigen, dass Krebsfrüherkennungsmaßnahmen für Menschen mit Störungen der Intelligenzentwicklung häufig nicht zugänglich sind. Wie kann diese Lücke geschlossen werden?

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise